UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.082

Sortiert nach

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

Scientific reports, 2021-09, Vol.11 (1), p.18708-18708, Article 18708

2021

Volltextzugriff (PDF)

Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study

Clinical chemistry (Baltimore, Md.), 2017-07, Vol.63 (7), p.1261-1270

2017

Volltextzugriff (PDF)

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study

Diabetologia, 2015-03, Vol.58 (3), p.464-473

2015

Volltextzugriff (PDF)

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study

Diabetologia, 2015-09, Vol.58 (9), p.2035-2044

2015

Volltextzugriff (PDF)

Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort

Human mutation, 2002-03, Vol.19 (3), p.311-311

2002

Volltextzugriff (PDF)

Comparison of Insulin Resistance, Metabolic Syndrome and Adiponectin in Overweight Bipolar Patients Taking Sodium Valproate and Controls

Australian and New Zealand journal of psychiatry, 2009-01, Vol.43 (1), p.53-60

2009

Volltextzugriff (PDF)

All-Cause Mortality in the Canterbury (New Zealand) Insulin-Treated Diabetic Registry Population

Diabetes care, 2001-01, Vol.24 (1), p.56-63

2001

Volltextzugriff (PDF)

Cause-specific mortality in insulin-treated diabetic patients: A 20-year follow-up

Diabetes research and clinical practice, 2008-04, Vol.80 (1), p.16-23

2008

Volltextzugriff (PDF)

Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study

Diabetes research and clinical practice, 2001-08, Vol.53 (2), p.113-120

2001

Volltextzugriff (PDF)

Plasma retinol-binding protein is not a marker of insulin resistance in overweight subjects: A three year longitudinal study

Clinical biochemistry, 2008-09, Vol.41 (13), p.1034-1038

2008

Volltextzugriff (PDF)

Urban–rural variation in childhood type 1 diabetes incidence in Canterbury, New Zealand, 1980–2004

Health & place, 2011-01, Vol.17 (1), p.248-256

2011

Volltextzugriff (PDF)

All-cause mortality in insulin-treated diabetic patients: A 20-year follow-up

Diabetes research and clinical practice, 2008-04, Vol.80 (1), p.e6-e9

2008

Volltextzugriff (PDF)

An ABCA1 truncation shows no dominant negative effect in a familial hypoalphalipoproteinemia pedigree with three ABCA1 mutations

Biochemical and biophysical research communications, 2011-06, Vol.409 (3), p.400-405

2011

Volltextzugriff (PDF)

Homocysteine, glycine betaine, and N, N-dimethylglycine in patients attending a lipid clinic

Metabolism, clinical and experimental, 2005, Vol.54 (1), p.1-14

2005

Volltextzugriff (PDF)

Is population mixing associated with childhood type 1 diabetes in Canterbury, New Zealand?

Social science & medicine (1982), 2009-02, Vol.68 (4), p.625-630

2009

Volltextzugriff (PDF)

Relationship between plasma coenzyme Q10 , asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy

Atherosclerosis, 2011-09, Vol.218 (1), p.188-193

2011

Volltextzugriff (PDF)

Homozygous familial hypercholesterolaemia and treatment by LDL apheresis

New Zealand medical journal, 2010-07, Vol.123 (1319), p.79-82

King, Richard I

2010

Volltextzugriff (PDF)

Seasonality of birth and onset of clinical disease in children and adolescents (0-19 years) with type 1 diabetes mellitus in Canterbury, New Zealand

Journal of pediatric endocrinology & metabolism : JPEM, 2002-05, Vol.15 (5), p.645

2002

Volltextzugriff (PDF)

Considerable temporal variability in glucose reference curves in humans for a year period

Nutrition research (New York, N.Y.), 2008-08, Vol.28 (8), p.495-500

2008

Volltextzugriff (PDF)

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

Circulation (New York, N.Y.), 2021-12, Vol.144 (23), p.1845-1855

2021

Volltextzugriff (PDF)

Is type 1 diabetes transmissible by bone marrow allograft?

Diabetes care, 2002-04, Vol.25 (4), p.799-800

2002

Volltextzugriff (PDF)

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2015-01, Vol.385 (9965), p.331-340

2015

Volltextzugriff (PDF)

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

The New England journal of medicine, 2019-01, Vol.380 (1), p.11-22

2019

Volltextzugriff (PDF)

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2016-04, Vol.315 (15), p.1580

2016

Volltextzugriff (PDF)

Incidence of type 1 diabetes mellitus diagnosed before age 20 years in Canterbury, New Zealand over the last 30 years

Journal of pediatric endocrinology & metabolism : JPEM, 2002-05, Vol.15 (5), p.637

2002

Volltextzugriff (PDF)

1 – 25 von 1.082

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.037)
Mit Volltextzugriff
(901)

Publikationsform

Artikel
(1.081)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes

Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study

Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study

Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort

Comparison of Insulin Resistance, Metabolic Syndrome and Adiponectin in Overweight Bipolar Patients Taking Sodium Valproate and Controls

All-Cause Mortality in the Canterbury (New Zealand) Insulin-Treated Diabetic Registry Population

Cause-specific mortality in insulin-treated diabetic patients: A 20-year follow-up

Predictors of mortality from type 2 diabetes mellitus in Canterbury, New Zealand; a ten-year cohort study

Plasma retinol-binding protein is not a marker of insulin resistance in overweight subjects: A three year longitudinal study

Urban–rural variation in childhood type 1 diabetes incidence in Canterbury, New Zealand, 1980–2004

All-cause mortality in insulin-treated diabetic patients: A 20-year follow-up

An ABCA1 truncation shows no dominant negative effect in a familial hypoalphalipoproteinemia pedigree with three ABCA1 mutations

Homocysteine, glycine betaine, and N, N-dimethylglycine in patients attending a lipid clinic

Is population mixing associated with childhood type 1 diabetes in Canterbury, New Zealand?

Relationship between plasma coenzyme Q10 , asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy

Homozygous familial hypercholesterolaemia and treatment by LDL apheresis

Seasonality of birth and onset of clinical disease in children and adolescents (0-19 years) with type 1 diabetes mellitus in Canterbury, New Zealand

Considerable temporal variability in glucose reference curves in humans for a year period

Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

Is type 1 diabetes transmissible by bone marrow allograft?

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

Incidence of type 1 diabetes mellitus diagnosed before age 20 years in Canterbury, New Zealand over the last 30 years

Aktive Filter

Suchergebnisse filtern